KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple
“Our focus at 2seventy is giving as much time as possible to patients who are battling cancer. We are moving rapidly to expand our clinical study program to determine utility of Abecma in newly diagnosed multiple myeloma patients with suboptimal response to transplant,” said Steve Bernstein, chief medical officer, 2seventy bio. “This population currently makes up more than half of multiple myeloma patients receiving transplant. Given the efficacy data from our collective KarMMa studies and well-established and predictable safety profile seen in studies replicated in the real-world, we believe there is tremendous potential for Abecma to help some of these patients earlier in their treatment path.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines